ABSTRACT
Recent advances in our understanding of the diagnosis, imaging, pathology, and clinical monitoring of multiple sclerosis (MS) have significantly increased our ability to successfully treat this often perplexing neurologic disorder. Magnetic resonance imaging (MRI) is now integral to the diagnostic process. Treatment of MS can be considered as three parallel pathways: treatment of relapses, symptom management, and long-term prevention of tissue injury.
Footnotes
↵* Dr. Fox has indicated that he has served as a consultant or lecturer for the Accorda Therapeutics, Biogen Idec, Genentech, Merck, Questor Pharmaceuticals, Serono, and Teva Neuroscience corporations.
↵† Dr. Bethoux has indicated that he has served as a lecturer for the Biogen Idec corporation.
↵‡ Dr. Cohen has indicated that he has served as a consultant for the Biogen Idec and Teva Neuroscience corporations and has received research support from the Biogen Idec corporation.
- © 2006 The Cleveland Clinic Foundation. All Rights Reserved.
